Protagonist Therapeutics (PTGX) Gains from Investment Securities (2015 - 2020)
Protagonist Therapeutics (PTGX) posted Gains from Investment Securities of $549000.0 for Q1 2020, up 4.57% sequentially from $525000.0 in Q1 2016.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) Gains from Investment Securities (2015 - 2020) Analysis & Trends
Protagonist Therapeutics has reported Gains from Investment Securities for 3 years, with the latest figure at $549000.0 in Q1 2020.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $549000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $549000.0 (changed N/A YoY) and the FY2016 annual result came in at $525000.0, up 196.69% from the prior year.
- Gains from Investment Securities advanced to $549000.0 in Q1 2020 per PTGX's latest filing, from $525000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $549000.0 in Q1 2020 and troughed at $525000.0 in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 549,000.00 |
| Mar 31, 2016 | 525,000.00 |
| Dec 31, 2015 | 116,000.00 |
| Sep 30, 2015 | -805,000.00 |
| Jun 30, 2015 | 136,000.00 |